by admin | Nov 25, 2019 | Funding
Azeria Therapeutics, a newly formed pioneer factor drug discovery company, announced a £32 million Series B financing in which Syncona has committed £29.5 million alongside existing investor the CRT Pioneer Fund. Azeria was originally founded in 2017 by Sixth Element...
by admin | Nov 11, 2019 | Funding
A company developing a means to edit RNA has raised more than $30 million in a venture capital funding round. Seattle-based Shape Therapeutics, or ShapeTx, said that it had raised a $35.5 million Series A financing, led by New Enterprise Associates and with...
by admin | Oct 21, 2019 | Licensing
ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates. Under the terms of the agreement, Avacta Group (Cambridge, UK) will provide three small Affimer proteins designed to bind to...
